Arno wobbling as it questions if onapristone has a future

5 January 2017

US biopharma Arno Therapeutics (OTCQB: ARNI) had lost nearly 22% of its already limited value by mid-morning on Thursday, after it announced that it was not going to enroll the remaining three patients in a Phase II trial.

The trial is a study of onapristone in combination with abiraterone acetate in men with advanced castration-resistant prostate cancer (CRPC) who have failed with the latter drug alone.

There were hopes that the combination of onapristone and abiraterone acetate, which is sold under the brand name Zytiga by subsidiaries of the US health care giant Johnson & Johnson (NYSE: JNJ), would provide a potential new treatment for men with prostate cancer and a significant opportunity for Arno.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK